Samuel Wilkinson is a psychiatrist, researcher, and Associate Professor at Yale University, where he serves as the Associate Director of the Yale Depression Research Program. He has been studying, and using, ketamine as a rapid-acting antidepressant since well before the advent of high-street ketamine clinics and mail-order injectables. That dual perspective across clinical research and real-world…
